Discounting: Technical issues in economic evaluations of vaccination

Vaccine

Volumn 17, Issue SUPPL. 3, 1999, Pages

  Tasset, Anne ^a   Nguyen, Van Hung ^a   Wood, Susan ^a   Amazian, Kamelia ^b  

^a Pasteur Merieux Connaught Intl   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Cost effectiveness; Discounting; Time preferences; Vaccination

Indexed keywords

CONFERENCE PAPER; ECONOMIC EVALUATION; MATHEMATICAL MODEL; METHODOLOGY; PRIORITY JOURNAL; VACCINATION;

EID: 0032752194     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00298-4     Document Type: Conference Paper

References (54)

1. Keeler EB, Cretin S. Discounting of life-saving and other nonmonetary effects. Mgmt Sci 1983;29(3):300-6.
2. Weinstein MC, Stason WB. Foundation of cost-effectiveness analysis for health and medical practices. New Engl J Med 1977;296(3):716-21.
3. Krahn M, Gafni A. Discounting in the economic evaluation of health care interventions. Med Care 1993;31(5):403-18.
4. Viscusi WK. Discounting health effects for medical decisions: 126-147. In: Sloan FA, editor. Health Care. Costs, Benefits, and effectiveness of Pharmaceuticals and other medical technologies. Cambridge: Cambridge University Press, 1995.
5. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford Medical Publications, 1996.
6. Martens L, van Doorslaer E. Dealing with discounting. An application to the cost-effectiveness of intracoronary thrombolysis with streptokinase. Int J Technol Assess Health Care 1990;6:139-45.
7. Goodin RE. Discounting discounting. Jnl Publ Pol 1981;2(1):53-72.
8. Ganiats TG. Discounting in Cost-Effectiveness Research. Med Decis Making 1994;14(3):298-300.
9. Parsonage M, Neuburger H. Discounting and Health benefits. Health Econ 1992;1:71-9.
10. Sheldon TA. Discounting in Health care decision-making: time for a change? J Public Health Med 1992;14(3):250-6.
11. Coyle D, Tolley K. Discounting of Health Benefits in the Pharmacoeconomic Analysis of Drug Therapies. An issue for debate? PharmacoEconomics 1992;2(2): 153-62.
12. Olsen JA. On what basis should health be discounted? Journal of Health Economics 1993;12:39-53.
13. Fuchs VR, Zeckhauser R. Valuing Health-A "Priceless" Commodity. AEA papers and proceedings-Lessons from health economics 1987;77(2):263-8.
14. Lipscomb J. Time Preference for Health in Cost Effectiveness Analysis. Med Care 1989;27(3):S233-S253.
15. Ganiats, TG. Prevention, Policy, and Paradox: What is the value of future Health? Am J Prev Med 13(1):12-17.
16. Antonanzas F, Forcen T, Garuz R. Analisis de coste-efectividad de la vacunacion frente al virus de la hepatitis B. Med Clinic (Barc) 1992;99(2):41-6.
17. Barboza RF, Rivero D, Echeverria B, Machado IV. Costo-beneficio de la vacunacion contra la hepatitis B en trabajadores de hospitales de Venezuela. Bol Sanit Panam 1991;111(1):16-23.
18. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Inter Med 1993;118(4):298-306.
19. Demicheli V, Jefferson TO. Cost-benefit analysis of the introduction of mass vaccination against hepatitis B in Italy. J Public Health Med 1992;14(4):367-75.
20. Everett WD. Hepatitis B prevention strategies: A benefit-cost analysis of immune serum globulin, hepatitis B immune globulin, and hepatitis B vaccine in the military. Am J Prev Med 1986;2(6):359-66.
21. Fabrizi F, Di Filippo S, Marcelli D, Guarnori I, Raffaele L, Crepaldi M, Erba G, Locatelli F. Recombinant Hepatitis B vaccine use in chronic hemodialysis patients. Long term evaluation and cost-effectiveness analysis. Nephron 1996;72:536-43.
22. Fenn P, Gray A, McGuire A. An economic evaluation of universal vaccination against hepatitis B virus. J Infect 1996;32(3):197-204.
23. Ginsberg GM, Berger S, Shouval D. Cost-benefit analysis of a nation-wide inoculation programme against viral hepatitis B in an area of intermediate endemicity. Bulletin of the WHO 1992;70(6):757-67.
24. Guillen Grima F, Espin Rios MI. Analisis coste-effetividad de las distintas alternativas de vacunacion universal frente a la hepatitis B en la region de Murcian. Med Clin (Barc) 1995;104(4):130-6.
25. Hall AJ, Robertson RL, Crivelli PE, Lowe Y, Inskip H, Snow SK, Whittle H. Cost-effectiveness of hepatitis B vaccine in the Gambia. Transactions of the Royal Society of Tropical Medicine and Hygiene 1993;87:333-6.
26. Hatziandreu EJ, Hatzakis A, Hatziyannis S, Kane MA, Weinstein MC. Cost-effectiveness of hepatitis B vaccine in Greece. Int J Technol Assess Health Care 1991;7(3):256-62.
27. Hicks RA, Cullen JW, Jackson MA, Burry VF. Hepatitis B Virus Vaccine. Cost-Benefit analysis of its use in a children's hospital. Clin Pediatr 1989;28(8):359-65.
28. Jönsson B, Horisberger B, Bruguera M, Matter L. Cost-benefit analysis of hepatitis-B vaccination. A computerised decision model for Spain. Int J Technol Assess Health Care 1991;7(3):379-402.
29. Kerleau M, Flori YA, Nalpas B, Lanoé JL, Berthelot P, Fardeau-Gautier M. Analyse coût-avantage d'une politique de prévention vaccinale de l'hépatite virale B. Rev Epidém et Santé Publ 1995;43:48-60.
30. Krahn M, Detsky AS. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis. Med Decis Making 1993;13:4-20.
31. Mangtani P, Hall AJ, Normand CE. Hepatitis B vaccination: the cost effectiveness of alternative strategies in England and Wales. J Epidemio Community Health 1995;49(3):238-44.
32. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995;274(15):1201-8.
33. Mauskopf JA, Bradley CJ, French MT. Benefit-cost analysis of hepatitis B vaccine programs for occupationally exposed workers. J Occup Med 1991;33(6):691-8.
34. Mulley AG, Silverstein MD, Dienstag JL. Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. New Engl J Med 1982;307(11):644-52.
35. Oddone EZ, Cowper PA, Hamilton JD, Feussner JR. A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients. HSR: Health Services Research 1993;28(1):97-121.
36. Tormans G, Van Damme P, Carrin G, Clara R, Eylenbosch W. Cost-effectiveness analysis of prenatal screening and vaccination against hepatitis B virus - the case of Belgium. Soc Sci Med 1993;37(2):173-81.
37. Van Hout BA, Roode ME, Barendrecht J, Van Hattum J. Costs and effects of universal vaccination strategies towards hepatitis B in the Netherlands. Eur J Gastroenterol Hepatol 1996;8:41.
38. Wiebe T, Fergusson P, Home D, Shanahan M, Macdonald A, Heise L, Roos LL. Hepatitis B immunization in a low-incidence province of Canada: comparing alternative strategies. Med Decis Making 1997;17(4):472-82.
39. Williams JR, Nokes DJ, Anderson RM. Target Hepatitis B vaccination - a cost effective immunisation strategy for the UK? J Epidemiol Community Health 1996;50:667-73.
40. Chapman GB, Elstein AS. Valuing the future: Temporal discounting of health and money. Med Decis Making 1995;15:373-86.
41. Olsen JA. Time preferences for health gains: an empirical investigation. Health Econ 1993;2:257-65.
42. Redelmeier DA, Heller DN. Time preference in Medical decision making and Cost-Effectiveness Analysis. Med Decis Making 1993;13:212-7.
43. Cairns JA, Van Der Pol MM. Constant and decreasing timing aversion for saving lives. Soc Sci Med 1997;45(11):1653-9.
44. Cairns JA, Van Der Pol MM. Saving future lives. A comparison of three discounting models. Health Econ 1997;6:341-50.
45. Cropper ML, Aydede SK, Portney PR. Rates of Time Preference for Saving Lives. American Economic Review 1992;82(2):469-72.
46. Horowitz JK, Carson RT. Discounting Statistical Lives. Journal of Risk and Uncertainty 1990;3:403-13.
47. Viscusi WK, Moore MJ. Rates of Time Preference and Valuations of the Duration of Life. J Public Health (North Holland) 1989;38:297-317.
48. Christensen-Szalanski JJ. Discount functions and the measurement of patients' values. Med Decis Making 1984;4:47-58.
49. Dolan P, Gudex C. Time preference, duration and health state valuations. Health Econ 1995;4:289-99.
50. Harvey CM. The reasonableness of non-constant discounting. Journal of Public Economics North Holland 1994;53:31-51.
51. Gafni A. Time in Health: Can we measure Individuals' "Pure Time Preferences"? Med Decis Making 1995;15:31-7.
52. MacKeigan LD, Narson LN, Draugalis JR, Bootman JL, Burns LR. Time preferences for health gains versus health losses. PharmacoEconomics 1993;3(5):374-86.
53. Read JL, Quinn RJ, Berwick DM, Fineberg HV, Weistein MC. Preferences for Health Outcomes. Comparison of Assessment Methods. Med Decis Making 1984;4(3):315-29.
54. West RR. Discounting the future: influence of the economic model. J Epidemiol Community Health 1996;50:239-44.